This report is tailored for C-level executives, business development professionals, licensing managers, legal advisors, and anyone involved in pharmaceutical and biotechnology deal-making. It provides ...

Artificial intelligence is rapidly inventing new drugs for diseases from Parkinson's disease and antibiotic-resistant superbugs to rare lung conditions.

The rapid advancement of Artificial Intelligence has moved us from simple chatbots to autonomous agents. These agents do not just answer questions; they plan, use tools, and execute tasks with minimal ...

His job is to reimagine the future of drugmaking using that similarly trendy branch of computer science, artificial intelligence (AI). He is applying this to transferring as much of the load as ...

Did the writers become lazy? Did seeing a perfect AI suggestion make them suppress their own unique voices? The data says no. When Padmakumar and He ...

What we are facing with AI is a world in which the systems we depend on are too complex to fully understand, too embedded to ...

Recursion Pharmaceuticals (RXRX) is back in focus after reporting fourth quarter and full year 2025 results, highlighting much higher quarterly revenue, a smaller net loss, and fresh commentary on its ...

Need a quote from a Motley Fool analyst? Over the past decade, Recursion Pharmaceuticals, Inc. has built something truly special: a differentiated platform pioneering the integration of large-scale ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the most promising penny stocks under $5 to buy. On February 25, Recursion Pharmaceuticals reported its financial results for Q4 and the full ...

Shares of Recursion Pharmaceuticals (RXRX) spiked on Wednesday after the AI-driven drug developer significantly exceeded Street forecasts with its Q4 2025 financials, thanks primarily to a milestone ...